Most SCLC patients survive one year or less after diagnosis. Our aim is to develop a drug against SCLC, which is both more effective than the current treatment recommendations and which also leads to fewer side effects. The hypothesis that we want to evaluate is whether treatment with L12 shows a better effect than the therapies that are available today, as well as evaluate basic pharmacokinetic properties of the molecule.
Menu